Close menu
Open menu
Identification of Novel Cancer-Specific Splice Variants Using Oxford BioTherapeutics' Ultra-High Sensitivity Tissue Membrane Proteomics Database, OGAP®-Verify, for First-in-class ADCs and Other Therapeutic Antibodies
Addressing Unmet Clinical Oncology Needs Through a Novel Therapeutic ADC Target Space in Cancer Patient Tissue Biopsies Using
OGAP®-Verify
Novel Target Identification Using Oxford BioTherapeutics' Proprietary Proteomics Target Discovery, OGAP(R), for First-in-Class ADCs and Other Antibody Therapeutics
Oxford BioTherapeutics and ImmunoGen Partner to Develop Multiple First-in Class Antibody-Drug Conjugates in Cancer Indications with High Unmet Clinical Need
A Novel B7-H6-targeted IgG-like T-cell Engaging Antibody for the Treatment of Gastrointestinal Tumors.
Identification and validation of a novel immuno-oncology target and selection of a therapeutic antibody candidate with a pharmacologically beneficial activity profile
Targeting CD205 with the antibody drugconjugate MEN1309/OBT076 is an active newtherapeutic strategy in lymphoma models
MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
AACR Annual Meeting 2018, Chicago, Illinois
Harnessing novel immune escape mechanisms for cancer therapeutics: OXAB1 target validation, proof of concept and preclinical development